To assess the implications of influencer promotion of prescription drugs on public health, particularly focusing on misinformation, regulatory gaps, and the impact of personal narratives on consumer perception.
Key Findings:
Influencers often present health information beyond their expertise, leading to misinformation.
Patient influencers may blur the line between personal experience and promotional messaging.
Some physician influencers provide accurate health information, suggesting a potential for a credentialing model.
Regulatory guidance on influencer content is vague and outdated, leading to enforcement challenges.
Parasocial relationships enhance trust in influencers, reducing recognition of persuasive intent in promotional content.
However, some physician influencers have been found to provide reliable information, indicating a potential positive role.
Interpretation:
The review highlights significant public health concerns due to the unregulated nature of influencer drug promotion, emphasizing the urgent need for improved regulatory frameworks and enhanced consumer education.
Limitations:
The evidence base is limited and heterogeneous, complicating comparisons.
Studies varied in design and methods, limiting conclusions about real-world outcomes.
The review was restricted to English-language literature, potentially missing relevant studies that could provide broader insights.
Conclusion:
Stronger regulatory guidance, standardized disclosure practices, and improved digital health literacy are essential to mitigate risks associated with influencer drug promotion, alongside a focus on consumer education.
Metabolomics analysis identified higher uric acid levels in patients with lipedema and lymphedema, although associations weakened following adjustment for renal insufficiency.
